---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-006360"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:36:06.901988+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics Q3 2024 net loss narrows to $1.8M; cash at $6.3M

## Summary
- Net loss of $1.8M ($0.05 per share) improved from $5.1M ($0.15) in Q3 2023.
- Cash and equivalents $6.3M; operations used $3.0M in Q3, down from $4.2M YoY.
- R&D expenses fell to $541K from $3.4M; total operating loss $1.9M vs $5.2M.
- Phase 2 gastric cancer trial data expected at a major conference in early 2025.
- Dr. Robert Kadlec joined board; new collaboration with Autonomous Therapeutics.

## SEC filing metadata
- accession: 0001171843-24-006360
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000117184324006360/0001171843-24-006360-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000117184324006360/f8k_111424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-006360
- JSON: https://secwatch.observer/filing/0001171843-24-006360.json
- Plain text: https://secwatch.observer/filing/0001171843-24-006360.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.